CT041 autologous CAR T-cell is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include CARsgen Therapeutics Co., Ltd. (2) and Beijing GoBroad Hospital (1). Registered phases: Phase 1, Observational and Phase 1/2. Conditions studied include Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05911217 | A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer |
Phase 1 | Recruiting |
| NCT07179484 | To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma (ClinicalTrials.gov ↗) Gastroesophageal Junction Adenocarcinoma |
Observational | Recruiting |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (ClinicalTrials.gov ↗) Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Cancer | 2 |
| Gastroesophageal Junction Adenocarcinoma | 2 |
| Gastric Adenocarcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| CARsgen Therapeutics Co., Ltd. | 2 |
| Beijing GoBroad Hospital | 1 |
| Register | CT041 autologous CAR T-cell trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CT041 autologous CAR T-cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CT041 autologous CAR T-cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.